Refocus Group

What Refocus Group does

Refocus Group, Inc. is a privately held U.S. medical-device company that has spent more than two decades developing the VisAbility Micro Insert System, an implantable binocular device designed to restore near vision in patients with presbyopia without compromising distance vision. The company describes the product as the world's first binocular presbyopic treatment that works outside the visual axis — a positioning that differentiates it from corneal inlays (e.g., AcuFocus's KAMRA, where current CEO Mike Judy previously worked) and intraocular lens-based approaches. The device remains investigational and limited by U.S. law to investigational use, with Refocus Group operating in a clinical-trial posture pending FDA approval and providing no disclosed revenue, pricing, or commercial launch date.

Name

Refocus Group

Legal name

Refocus Group, Inc.

Website

https://refocus-group.com

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

11–50 employees

Short description

Refocus Group is a privately held U.S. medical-device company developing the investigational VisAbility Micro Insert System, a binocular scleral implant designed to restore near vision in presbyopia patients while preserving distance vision, currently in clinical trials pending FDA approval.

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices

NAICS

Ophthalmic Goods Manufacturing (339115)

SIC

Ophthalmic Goods (3851)

akta.pro primary industry

Refractive Surgery Systems (Excimer/Femtosecond Lasers, Phakic IOL Systems, Wavefront/Guidance) (HLAHAJAG)

Keywords

• Ophthalmic medical devices
• Presbyopia treatment
• Intraocular micro inserts
• Refractive surgery devices
• Near vision correction

Headquarters

HQ city

Dallas

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Revenue will be generated from the sale of the VisAbility Micro Insert System to eye care professionals. The device is an investigational medical device currently in clinical trials, pending FDA approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Refocus Group develops the VisAbility™ Micro Insert System, an investigational implantable ophthalmic device designed to restore near vision in both eyes for patients with presbyopia without affecting distance vision. The system works outside the visual axis and is intended to be implanted by trained ophthalmologists and optometrists as a binocular treatment that reduces or eliminates dependence on reading glasses. The device is currently limited by U.S. law to investigational use, with Refocus Group conducting clinical trials to support future regulatory approval and commercial launch.

Product overview

Refocus Group offers a single unified product—the VisAbility™ Micro Insert System. This is an investigational medical device designed for the treatment of presbyopia, intended to restore near vision in both eyes while maintaining distance vision. The system represents the world's first binocular presbyopic treatment approach that works outside the visual axis, enabling patients to reduce or eliminate their dependence on reading glasses.

Differentiator

Problem solved

Functional benefit

Brands

• VisAbility: VisAbility™ Micro Insert System is an investigational medical device for near vision correction in patients with presbyopia. It is the world's first binocular presbyopic treatment that works outside the visual axis.

Products and services

• VisAbility™ Micro Insert System Investigational binocular ophthalmic implant designed to restore near vision in patients with presbyopia without affecting distance vision; works outside the visual axis and is intended to reduce or eliminate dependence on reading glasses. Implanted by trained ophthalmologists and optometrists in the eye care professional setting.

Quantifiable outcome

• Patients who participated in clinical trials showed improved near vision in both eyes and reduced need for reading glasses

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Alcon: Global ophthalmic medical device leader offering multifocal and presbyopia-correcting IOLs (e.g., PanOptix) along with refractive surgery platforms. Overlaps with Refocus in the presbyopia treatment market but operates at vastly greater scale across the full ophthalmic portfolio.
• Carl Zeiss Meditec: Manufactures refractive surgery systems (SMILE, excimer lasers) and ophthalmic IOLs, including presbyopia-correcting lenses. Comparable as a refractive/presbyopia device incumbent with global distribution into ophthalmic surgical centers.
• Johnson & Johnson Vision: J&J Vision competes in presbyopia through the TECNIS Symfony extended depth-of-focus IOL and other refractive surgical platforms. As a broad incumbent with a deep cataract/refractive sales force, it represents both an overlapping product offering and a competitive commercialization benchmark.
• Bausch + Lomb: Major ophthalmic device and vision care company whose surgical franchise includes accommodating IOLs such as Crystalens for presbyopia. CEO Mike Judy previously led global surgical marketing at Bausch + Lomb, and the company competes in the same presbyopia correction category as VisAbility.

Emerging players

• Orasis Pharmaceuticals: Develops a corrective eye drop therapy (CSF-1 / pilocarpine-based) for presbyopia. Targets the same patient population seeking to reduce dependence on reading glasses, representing a non-invasive competitive alternative to Refocus's surgical implant.
• STAAR Surgical: Makes the Visian Implantable Collamer Lens (ICL), a refractive implant placed in the eye for vision correction. Comparable to Refocus as an implantable refractive device company, though addressing myopia rather than presbyopia, and at a different commercial stage.
• Glaukos Corporation: Pioneered minimally-invasive scleral/suprachoroidal implant-based approaches in ophthalmology (initially for glaucoma, now expanding). Comparable to Refocus for its expertise in implant-based ophthalmic platforms that work outside the visual axis, even though the therapeutic indication differs.
• Visus Therapeutics: Clinical-stage company developing pharmacologic presbyopia correction treatments (e.g., brimonidine-based formulations). Competes for presbyopia share via eye drops, intersecting with Refocus on patient indication while pursuing a different delivery modality.
• Lenz Therapeutics: Late-stage clinical company developing pharmacologic eye drops for presbyopia (e.g., aceclidine-based therapies). Competes for the same presbyopia treatment opportunity as Refocus via a non-surgical mechanism, making it a category competitor rather than a direct device peer.

Direct peers

• AcuFocus: AcuFocus developed the KAMRA corneal inlay, the closest direct competitor — a small-aperture implant for presbyopia. Refocus CEO Mike Judy was AcuFocus's Chief Commercial Officer, making this the single most directly comparable company in terms of product category, mechanism (implantable presbyopia device), and commercial model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/refocus-group-144846555556360
• LinkedInlinkedin.com/company/refocus-group-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Refocus Group